Premium
Contrast agents for MRA: Future directions
Author(s) -
Knopp M.V.,
von TenggKobligk H.,
Floemer F.,
Schoenberg S.O.
Publication year - 1999
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/(sici)1522-2586(199909)10:3<314::aid-jmri13>3.0.co;2-y
Subject(s) - gadolinium , contrast (vision) , magnetic resonance angiography , magnetic resonance imaging , nuclear magnetic resonance , computer science , radiology , medicine , chemistry , physics , artificial intelligence , organic chemistry
The purpose of this review is to outline recent developments in contrast agents for magnetic resonance angiography (MRA) and to give some idea of what the future might hold. Up to now, non‐binding gadolinium (Gd) chelates have been the agents used for MRA. Modified paramagnetic Gd‐based agents with varying degrees of protein interaction have been developed, and these, together with new superparamagnetic compounds, are currently under clinical evaluation. It is likely that two different types of contrast agent will soon be available: extracellular agents for first‐pass MRA and intravascular agents mainly for steady‐state MRA. Several agents also exhibit certain tissue specific properties in addition to conventional extracellular properties. This will lead to more comprehensive imaging approaches.J. Magn. Reson. Imaging 10:314–316, 1999. © 1999 Wiley‐Liss, Inc.